April 2025 — As the biopharma industry embraces increasingly sophisticated delivery and diagnostic technologies, Litchlab officially launches its full-service Magnetic Nanoparticle (MNP) CDMO Platform. Designed to address the rising demand for precision drug delivery, non-invasive imaging, regenerative therapies, and smart diagnostics, Litchlab’s offering spans early-stage development, scalable GMP manufacturing, analytical characterization, and global regulatory support, helping innovators accelerate groundbreaking products to clinical success.
According to recent industry reports, the global magnetic nanoparticle market is expected to surpass USD 10 billion by 2030, driven by applications in oncology, neurology, infectious diseases, and personalized medicine. Litchlab’s investment in modular, scalable MNP technology reflects its strategic commitment to support high-value, high-impact therapeutic pipelines worldwide.
✅ Diverse Magnetic Cores with Tunable Properties
Superparamagnetic Iron Oxide Nanoparticles (SPIONs): Fe₃O₄, γ-Fe₂O₃
Doped Ferrite Nanoparticles: MnFe₂O₄, CoFe₂O₄ for optimized magnetic responsiveness
Core-shell designs for dual imaging and therapeutic functionalities
✅ Advanced Surface Modification
PEGylation, polysaccharide, lipid, and silica coatings for biocompatibility and stealth
Active targeting strategies: Antibody, peptide, aptamer functionalization
Smart hybrid systems: MNPs combined with liposomes, polymers, hydrogels
✅ Flexible Delivery Formats
Injectable nanosuspensions for systemic and local therapies
Implantable MNP scaffolds for controlled release
Smart magnetically triggered release systems for on-demand therapy
Integrated theranostic solutions combining imaging and treatment
✅ Wide Drug Compatibility
Small molecules, chemotherapy agents
Peptides and proteins
Monoclonal antibodies (mAbs)
siRNA, mRNA, DNA therapeutics
Stem cells and extracellular vesicles (EVs)
Precise control over particle size (10–200 nm), morphology, and magnetic strength
Scalable synthesis protocols ensuring batch-to-batch reproducibility
Aseptic processing and sterile formulation expertise
Flexible scale-up: From grams to kilograms for clinical trials and commercial launch
Integrated fill-finish capabilities for injectable formulations
Physicochemical characterization: Size, zeta potential, magnetization curves, relaxivity (MRI contrast performance)
In vitro and in vivo biocompatibility studies: Cytotoxicity, hemocompatibility, immunogenicity
Release kinetics and stability studies under ICH-compliant protocols
Full documentation packages for IND, IMPD, and NDA submissions
Support for FDA, EMA, and NMPA pathways
| Application Area | Example Projects |
|---|---|
| Oncology | Magnetically guided chemotherapeutic delivery + hyperthermia treatment |
| Neurology | MRI imaging and targeted neuroprotective drug release |
| Infectious Disease | MNP-based point-of-care biosensors for rapid pathogen detection |
| Regenerative Medicine | Magnetic tracking of stem cells in tissue regeneration |
| Precision Diagnostics | Smart diagnostic assays with MNP signal amplification |
✔️ Fully integrated MNP CDMO platform from discovery to GMP production
✔️ Expertise in designing smart multifunctional magnetic systems
✔️ Rapid scalability from preclinical R&D to Phase I/II/III clinical supply
✔️ Strong regulatory experience supporting global filings
✔️ Customization for combination products (e.g., drug + device solutions)
✔️ Dedicated project management and technical transfer teams
📞 Partner with Litchlab to accelerate your magnetic nanoparticle innovation journey.
🔗 Learn more: www.litchlab.com
📧 Contact us: Sales@litchlab.com
